Hims & Hers Health stock corrected after earnings because of the outlook on its key GLP-1 medication. See why I rate HIMS a ...

Hims & Hers Health is a top growth stock with strong cash flow, no debt, and an innovative AI-powered platform. Learn more on ...

Of the 22 guru strategies we follow, HIMS rates highest using our Small-Cap Growth Investor model based on the published strategy of Motley Fool. This strategy looks for small cap growth stocks ...

Hims & Hers Health (HIMS) stock enjoyed a 10% jump in price last week on news that the company plans to continue offering compounded versions of Ozempic and Wegovy. This approach is in response to ...

Of the 22 guru strategies we follow, HIMS rates highest using our Small-Cap Growth Investor model based on the published strategy of Motley Fool. This strategy looks for small cap growth stocks ...

Hims & Hers is shutting down the dermatology business it acquired in 2021, BI has learned. It said it's closing the skincare site Apostrophe to centralize its teledermatology offerings. Hims ...

Hims & Hers Health, Inc. (HIMS) shares rallied 5.7% in the last trading session to close at $34.75. This move can be attributable to notable volume with a higher number of shares being traded than ...

Hims & Hers Health (NYSE:HIMS) has taken investors on a wild ride in 2025. The stock surged nearly 200% earlier this year, reaching an all-time high by late February – only to plunge by half in ...

Keep reading to see if Hims is right for you. In this article, we use “male and female” to refer to someone’s sex as determined by their chromosomes, and “men and women” when referring ...

The knockoff surge was led by Hims & Hers Health, the telehealth firm that began selling the drugs last spring.